Sherene Loi, Medical Oncologist, Lab Head of Breast Oncology Clinical Trials at Peter MacCallum Cancer Centre, Australia, shared a post by Paolo Tarantino, adding:
“ T-DXd: A New Hope becomes the New World Order in HER2 – Positive BC.
3 big read outs for T-Dxd in breast cancer Where will we place T-Dxd preferentially if avail. and all data looks good?
1) residual disease
2) 1L metastatic
3) neoadjuvant with TCHP
Vote (pre ESMO).”
Quoting Paolo Tarantino‘s post:
“After improving OS for patients with metastatic disease, the topo1 ADC wave is now reaching its most ambitious goal: preventing recurrence.
DB-05 is positive: adjuvant T-DXd improves iDFS over T-DM1.
No info on ILD in the press release. Hoping for no G5.”
More posts featuring Paolo Tarantino and Sherene Loi on OncoDaily.